Bitcoin price today: gains to $120k, near record high on U.S. regulatory cheer
Monday saw Truist Securities maintaining a Hold rating and a $90.00 price target for Globus Medical (NYSE:GMED) shares, with analyst targets ranging from $90 to $115. The decision comes after the company’s fourth-quarter earnings report, which showed impressive revenue growth of 60.6% year-over-year and solid performance, but was overshadowed by questions surrounding the recent acquisition of Nevro Corp (NYSE:NVRO), a deal announced on February 6, 2023.
Truist Securities acknowledged the company’s ability to sustain mid-single-digit growth above its core spine end-market. According to InvestingPro data, the stock’s RSI suggests oversold territory, potentially presenting an opportunity despite trading at a high P/E ratio of 118.5. The firm also noted that the earnings per share guidance provided by Globus Medical appears conservative, especially considering the synergies from the NuVasive (NASDAQ:NUVA) deal are surpassing management’s initial targets.
Despite the positive outlook on growth and the low valuation of the Nevro deal, Truist Securities expressed caution. They pointed out that the near-term dilution from the deal could potentially slow down Globus Medical’s margin re-expansion, which in turn might limit the potential for multiple expansions in the stock’s valuation. For deeper insights into GMED’s valuation and 12 additional exclusive ProTips, check out the comprehensive research report available on InvestingPro.
Analysts at Truist Securities are looking for clearer signs of accelerated revenue growth and successful integration of Nevro without any unexpected negative surprises or setbacks before considering a rating change. Until then, they have opted to maintain their Hold stance on Globus Medical shares, even as the company maintains a strong financial health score of "GREAT" according to InvestingPro metrics.
In other recent news, Globus Medical reported strong financial results for the fourth quarter of 2024, with revenue reaching $657.3 million, a 6.6% increase year-over-year. The company’s earnings per share (EPS) for the quarter were $0.84, surpassing analysts’ expectations of $0.75. BTIG analyst Ryan Zimmerman responded to these results by raising the price target for Globus Medical to $94 while maintaining a Buy rating. The company’s Musculoskeletal Solutions segment reported revenue of $610.3 million, a 4.5% increase, while the Enabling Technologies segment saw a significant 43.5% growth to $47.0 million.
Globus Medical also announced an acquisition agreement with Nevro Corp, which is expected to impact the company’s 2025 financial guidance. The updated guidance projects revenue of $2.8 billion to $2.9 billion and an adjusted EPS of $3.10 to $3.40, reflecting the anticipated contributions from Nevro. Management has expressed that Nevro’s Spinal Cord Stimulation technology could enhance Globus Medical’s offerings in the Enabling Technologies division. The company has emphasized its commitment to innovation, having launched 18 new products in 2024 alone.
Globus Medical’s full-year revenue for 2024 was $2.519 billion, marking a 60.6% growth from the previous year, with a non-GAAP EPS of $3.04. The company continues to focus on strategic growth through product development and market expansion, with expectations of significant financial synergies from the Nevro acquisition in fiscal year 2026.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.